Your browser doesn't support javascript.
loading
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Höglinger, Günter U; Litvan, Irene; Mendonca, Nuno; Wang, Deli; Zheng, Hui; Rendenbach-Mueller, Beatrice; Lon, Hoi-Kei; Jin, Ziyi; Fisseha, Nahome; Budur, Kumar; Gold, Michael; Ryman, Davis; Florian, Hana.
Afiliação
  • Höglinger GU; German Center for Neurodegenerative Diseases, Munich, Germany; Department of Neurology, Technische Universität München, Munich, Germany; Department of Neurology, Hannover Medical School, Hannover, Germany. Electronic address: hoeglinger.guenter@mh-hannover.de.
  • Litvan I; Parkinson and Other Movement Disorders Center, University of California San Diego, La Jolla, CA, USA.
  • Mendonca N; Neuroscience, AbbVie Inc, North Chicago, IL, USA.
  • Wang D; Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USA.
  • Zheng H; Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USA.
  • Rendenbach-Mueller B; Neuroscience, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
  • Lon HK; Clinical Pharmacology and Pharmacometrics, AbbVie Inc, North Chicago, IL, USA.
  • Jin Z; Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USA.
  • Fisseha N; Neuroscience, AbbVie Inc, North Chicago, IL, USA.
  • Budur K; Neuroscience, AbbVie Inc, North Chicago, IL, USA.
  • Gold M; Neuroscience, AbbVie Inc, North Chicago, IL, USA.
  • Ryman D; Neuroscience, AbbVie Inc, North Chicago, IL, USA.
  • Florian H; Neuroscience, AbbVie Inc, North Chicago, IL, USA.
Lancet Neurol ; 20(3): 182-192, 2021 03.
Article em En | MEDLINE | ID: mdl-33609476

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paralisia Supranuclear Progressiva / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paralisia Supranuclear Progressiva / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article